Table 2.
Group | 2hPG (mmol/L) | FPG (mmol/L) | HbA1c (%) | |||
---|---|---|---|---|---|---|
|
|
|
||||
Before Treatment | After Treatment | Before Treatment | After Treatment | Before Treatment | After Treatment | |
Early SGLT2-i group (n = 88) | 13.52±4.26 | 7.24±2.21* | 8.09±2.56 | 5.58±1.76* | 8.34±2.68 | 5.12±1.64* |
Late SGLT2-i group (n = 90) | 13.81±4.02 | 8.36±2.65* | 8.57±2.75 | 6.24±2.01* | 8.69±2.79 | 6.47±2.05* |
t | 0.467 | 3.059 | 1.205 | 2.329 | 0.853 | 4.845 |
P | 0.641 | 0.003 | 0.230 | 0.021 | 0.395 | < 0.001 |
P < 0.05 compared to pre-treatment within the same group;
FPG, fasting plasma glucose; 2hPG, 2-hour postprandial glucose; HbA1c, glycated hemoglobin; SGLT2-i, sodium-glucose cotransporter 2 inhibitor.